Table 1.
Baseline characteristics of patients.
| Decitabine (DAC) (n = 8) |
DAC combined with chemotherapy (n = 18) |
DAC combined with CIK (n = 5) |
|
|---|---|---|---|
| Sex | |||
| Male | 6 (75%) | 10 (55.6%) | 5 (100%) |
| female | 2 (25%) | 8 (44.4%) | 0 (0) |
| Age (years) | 55 (42–77) | 57 (28–84) | 55 (34–62) |
| ECOG performance status score | |||
| 0-1 | 7 (87.5%) | 16 (88.9%) | 5 (100%) |
| >1 | 1 (12.5%) | 2 (11.1%) | 0 (0) |
| International stage system | |||
| III | 2 (25%) | 1 (5.6%) | 0 (0) |
| IV | 6 (75%) | 17 (94.4%) | 5 (100%) |
| Number of previous treatments | |||
| More than two | 6 (75%) | 18 (100%) | 5 (100%) |
| Number of lesions before DAC treatment | |||
| ≤5 | 3 (37.5%) | 6* (33.3%) | 4 (80%) |
| >5 | 5 (62.5%) | 12 (66.7%) | 1 (20%) |
| Primary tumor type | |||
| Gastric cardia adenocarcinoma | 2 (25%) | 1 (5.6%) | — |
| Colorectal adenocarcinoma | 1 (12.5%) | 2 (11.2%) | — |
| Hepatocellular carcinoma | 1 (12.5%) | — | 4 (80%) |
| Intrahepatic bile ducts adenocarcinoma | 1 (12.5%) | — | — |
| Alveolar carcinoma | 1 (12.5%) | — | — |
| Malignant pleural tumors | 1 (12.5%) | — | — |
| Esophageal adenocarcinoma | 1 (12.5%) | 2 (11.2%) | — |
| Non-Hodgkin's lymphoma | — | 5 (28%) | — |
| Hodgkin's lymphoma | — | 1 (5.6%) | — |
| Lung adenocarcinoma | — | 4 (22.4) | — |
| Cervical squamous cell carcinomas | — | 1 (5.6%) | — |
| Ovary serous papillary cystadenocarcinoma | — | 1 (5.6%) | — |
| Tubal serous adenocarcinoma | — | 1 (5.6%) | — |
| Pancreatic cancer | — | — | 1 (20%) |
Note. Date is number (%) or media (range). NHL: Non-Hodgkin's lymphoma; ECOG: Eastern Cooperative Oncology Group; *one patient with an increased CA125 level.